Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions
Renal Transplant Infection
Interventions
DRUG

Study Group

Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.

DRUG

Control Group

Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of \< 1 at month 1, and BK data available and month 2,3, 6,9,12.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03762473 - Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection | Biotech Hunter | Biotech Hunter